Back

Influence of Lp(a) and systemic inflammation on all-cause mortality in a primary prevention population: data from our clinic database

25 August 2023 (10:15 - 10:50)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk assessment (1) Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Leslie Cho

Cleveland Clinic, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
Inferior vena cava wall thickness is associated with the presence and severity of cardiovascular disease.
Doctor K. Fujiyoshi (Kanagawa, JP)
Abstract Slides Video
Presentation thumbnail
Typical and atypical chest pain: an equivocal and dangerous definition
Doctor D. Cosmi (Perugia, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence of subclinical coronary artery atherosclerosis in the general population- apollo subclinical coronary atherosclerosis project (ASCAP)
Doctor L. Narra (Hyderabad, IN)
Abstract Slides Video
Presentation thumbnail
Non-HDL cholesterol and residual risk of myocardial infarction and death in statin-treated patients with and without diabetes
Doctor M. Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Carotid plaque score for stroke and cardiovascular risk prediction in a middle-aged cohort from the general population: the akershus cardiac examination 1950 study
Mr H. Ihle-Hansen (Gjettum, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular risk assessment (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Lipoprotein(a), high-sensitive c reactive protein, and long-term survival after coronary artery bypass grafting
thumbnail
Congress Presentation
The potential impact of residual inflammation and elevated Lipoprotein (a) levels in long-term cardiovascular patients' survival
thumbnail
Congress Presentation
The association of lipoprotein(a) with patient characteristics and mortality in a primary prevention cohort: data from our clinic database

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources